SCHEMBL93579

SCHEMBL93579

NC(N)CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27534769 0.97
SCHEMBL8961415 0.97
Hydrochloric Acid SCHEMBL8544926 0.97
Ethylene SCHEMBL8854307 0.94
SCHEMBL2491274 0.79 SLC22A6 (0.50)
SCHEMBL288510 0.79 SLC22A6 (0.50)
SCHEMBL338756 0.76
SCHEMBL6734053 0.76 SLC22A6 (0.47)
SCHEMBL28799207 0.76 SLC22A6 (0.47)
SCHEMBL447923 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2773 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282819-A1 MITOCHONDRIA-SPECIFIC PEPTIDE THAT CAN BE INTRACELLULARLY DELIVERED AT NANOMOLAR CONCENTRATION, AND USE THEREOF CAMP THERAPEUTICS INC. (KR) 2025-09-11 US claimed
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-09-04 US claimed
CN-116102488-B Process for preparing 2, 3-diaminopropionic acid derivatives having different amino groups in position 3 宁夏医科大学 2025-06-17 CN claimed
EP-3592761-B1 NEW ANTIBACTERIAL PRODUCTS UNIV LIVERPOOL (GB) 2025-05-14 EP claimed
EP-4532509-A1 INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS Polypeptide Laboratories Holding (PPL) AB (SE) 2025-04-09 EP claimed
EP-4529474-A1 RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS Erasmus University Rotterdam Medical Center (NL) 2025-04-02 EP claimed
US-20250099573-A1 SARS-COV-2 S PROTEIN POLYPEPTIDE ANTIGEN AND APPLICATION THEREOF CHINESE PLA GENERAL HOSPITAL (CN) 2025-03-27 US claimed
WO-2024253439-A1 COMPOSITIONS FOR PREVENTING OR TREATING OBESITY OR NON-ALCOHOLIC FATTY LIVER DISEASE COMPRISING MITOCHONDRIA-SPECIFIC PEPTIDES (주) 캠프테라퓨틱스 2024-12-12 WO claimed
US-20240327463-A1 ANTIBACTERIAL PRODUCTS THE UNIVERSITY OF LIVERPOOL (GB) 2024-10-03 US claimed
WO-2024167324-A1 COMPOSITIONS FOR PREVENTING OR TREATING KIDNEY OR LIVER DISEASES COMPRISING MITOCHONDRIA-SPECIFIC PEPTIDES (주) 캠프테라퓨틱스 2024-08-15 WO claimed
CN-1131950-A Recombinant C140 receptor and its agonists and antagonists COR THERAPEUTICS (US) 1996-09-25 CN claimed
EP-0730590-A1 NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-09-11 EP claimed
WO-1995014683-A1 NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-06-01 WO claimed
CN-1089606-A Antiretroviral acyl compounds CIBA GEIGY AG (CH) 1994-07-20 CN claimed
CN-1086222-A Amino acid derivatives, process for their preparation and pharmaceutical compositions containing them BOEHRINGER INGELHEIM KG (DE) 1994-05-04 CN claimed
CN-1080916-A The quinic tricyclic compound of anti-column foot, its preparation method and contain the pharmaceutical composition of this compound MENARINI FARMA IND (IT) 1994-01-19 CN claimed
CN-1068333-A Has hydrazine analog derivative of pharmacologically active and preparation method thereof CIBA GEIGY AG (CH) 1993-01-27 CN claimed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN claimed
US-4152493-A Process for eliminating metal ions from a metal ion-containing liquid with solid chelate resins TORAY INDUSTRIES, INC. (JP) 1979-05-01 US claimed